A 68-Year-Old Woman with ALK+ Non–Small Cell Lung Cancer

Karen Reckamp, MD, provides an overview of the case of a 68-year-old woman with ALK+ NSCLC, including the initial presentation, clinical work-up, treatment, and the importance of molecular testing.

Karen Reckamp, MD, reviews recent therapeutic findings and the treatment spectrum for ALK+ NSCLC, as well as her clinical experience in using some of these treatments.

An expert in the treatment of lung cancer discusses the use of brigatinib in this patient case and in general use for ALK+ metastatic NSCLC.

Karen Reckamp, MD, discusses the design, practical implications, and important findings from the ALTA-1L clinical trial.

An expert in the treatment of lung cancer gives insight for the sequencing of ALK inhibitors following disease progression, highlighting the instances of the development of brain involvement and rebiopsy.

An expert in the treatment of lung cancer gives insight for the sequencing of ALK inhibitors following disease progression, highlighting the instances of the development of brain involvement and rebiopsy.